Outcomes of COVID-19 in Cancer Patients who Developed Acute Kidney Injury During Hospitalization in a Tertiary Care Hospital in India

Ram Singh, H. Sagiraju, S. Krishnasamy, P. Sirohiya, B. Kumar, B. Ratre, S. Bhatnagar
{"title":"Outcomes of COVID-19 in Cancer Patients who Developed Acute Kidney Injury During Hospitalization in a Tertiary Care Hospital in India","authors":"Ram Singh, H. Sagiraju, S. Krishnasamy, P. Sirohiya, B. Kumar, B. Ratre, S. Bhatnagar","doi":"10.31557/apjcc.2022.7.3.515-517","DOIUrl":null,"url":null,"abstract":"Background: The development of acute kidney injury (AKI) in patients infected with COVID-19 has been observed to be associated with poor outcomes. Our study aimed to measure the outcomes of COVID-19 in cancer patients who developed AKI during hospitalization and the predictive baseline clinical and laboratory factors associated with the development of AKI. Materials and Methods: This retrospective cohort study was conducted at a COVID hospital that included only cancer patients with COVID-19 infection. Acute kidney injury (AKI) was defined according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria. The demographic, clinical, laboratory and outcomes data were collected from the hospital electronic database and abstracted from the case files. Results: Thirteen (12.8%) of the total 102 cancer patients developed AKI during hospitalization. Out of 13, 11 (84.6%) patients presented with hypoxemia during admission and required oxygen support. Breathlessness [Odds Ratio (OR) (95% CI): 5.8 (1.1-31.3)] or hypoxemia [OR 22.6 (2.6-194.5)] at the time of presentation and requirement of oxygen support [OR 7.5 (1.4-40.5)] were significantly associated with AKI after adjusting for age, gender, vaccination status and comorbidities. Median baseline values of inflammatory markers were significantly higher among those who developed AKI. Out of 102, 27 (26.5%) patients had in-hospital mortality. Mortality was high among those who developed AKI compared to those who didn’t develop AKI (92.3% vs 16.1%, p-value: <0.001). Conclusions: The cancer patients infected by COVID-19 and who developed AKI were more vulnerable to poor outcomes in terms of in-hospital mortality. The patients with severe disease at presentation and higher levels of baseline inflammatory markers CRP, ferritin, and D-Dimer were more susceptible to the development of AKI and in turn, led to a higher risk of in-hospital mortality in these patients. ","PeriodicalId":436394,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"287 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/apjcc.2022.7.3.515-517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The development of acute kidney injury (AKI) in patients infected with COVID-19 has been observed to be associated with poor outcomes. Our study aimed to measure the outcomes of COVID-19 in cancer patients who developed AKI during hospitalization and the predictive baseline clinical and laboratory factors associated with the development of AKI. Materials and Methods: This retrospective cohort study was conducted at a COVID hospital that included only cancer patients with COVID-19 infection. Acute kidney injury (AKI) was defined according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria. The demographic, clinical, laboratory and outcomes data were collected from the hospital electronic database and abstracted from the case files. Results: Thirteen (12.8%) of the total 102 cancer patients developed AKI during hospitalization. Out of 13, 11 (84.6%) patients presented with hypoxemia during admission and required oxygen support. Breathlessness [Odds Ratio (OR) (95% CI): 5.8 (1.1-31.3)] or hypoxemia [OR 22.6 (2.6-194.5)] at the time of presentation and requirement of oxygen support [OR 7.5 (1.4-40.5)] were significantly associated with AKI after adjusting for age, gender, vaccination status and comorbidities. Median baseline values of inflammatory markers were significantly higher among those who developed AKI. Out of 102, 27 (26.5%) patients had in-hospital mortality. Mortality was high among those who developed AKI compared to those who didn’t develop AKI (92.3% vs 16.1%, p-value: <0.001). Conclusions: The cancer patients infected by COVID-19 and who developed AKI were more vulnerable to poor outcomes in terms of in-hospital mortality. The patients with severe disease at presentation and higher levels of baseline inflammatory markers CRP, ferritin, and D-Dimer were more susceptible to the development of AKI and in turn, led to a higher risk of in-hospital mortality in these patients. 
COVID-19在印度三级医院住院期间发生急性肾损伤的癌症患者中的结果
背景:已观察到COVID-19感染患者发生急性肾损伤(AKI)与不良预后相关。我们的研究旨在测量住院期间发生AKI的癌症患者的COVID-19结局以及与AKI发展相关的预测基线临床和实验室因素。材料和方法:本回顾性队列研究在一家COVID医院进行,仅纳入了COVID-19感染的癌症患者。急性肾损伤(AKI)根据KDIGO(肾脏疾病:改善全球结局)标准定义。人口统计、临床、实验室和结局数据从医院电子数据库中收集,并从病例档案中摘录。结果:102例癌症患者中有13例(12.8%)在住院期间发生AKI。在13例患者中,11例(84.6%)患者在入院时出现低氧血症并需要氧气支持。在调整了年龄、性别、疫苗接种状况和合并症后,就诊时的呼吸困难[比值比(OR) (95% CI): 5.8(1.1-31.3)]或低氧血症[OR 22.6(2.6-194.5)]和氧支持需求[OR 7.5(1.4-40.5)]与AKI显著相关。在发生AKI的患者中,炎症标志物的中位基线值明显更高。在102例患者中,27例(26.5%)患者住院死亡。与未发生AKI的患者相比,发生AKI的患者死亡率较高(92.3% vs 16.1%, p值<0.001)。结论:在院内死亡率方面,感染COVID-19的癌症患者和发生AKI的患者更容易出现不良结局。病情严重且基线炎症标志物CRP、铁蛋白和d -二聚体水平较高的患者更容易发生AKI,进而导致这些患者住院死亡的风险更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信